Lexicon Pharmaceuticals vs SIGA Technologies
LXRX and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and SIGA compare
Lexicon Pharmaceuticals is the larger company, worth 4.0 times as much as SIGA Technologies ($792M against $196M).
Lexicon Pharmaceuticals grew revenue faster over the last twelve months (−29.0% versus −70.1% for SIGA Technologies).
SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of −5.2% compared with −147% at Lexicon Pharmaceuticals.
SIGA Technologies pays a dividend yielding 22.0%; Lexicon Pharmaceuticals does not pay one.
SIGA Technologies scores higher on the StockData Score (14 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | SIGA |
|---|---|---|
| Size and price | ||
| Market cap | $792M | $196M |
| Share price | $1.78 | $2.73 |
| Change, 1 year | 19.5% | −54.5% |
| Change, 5 years | −62.4% | −68.0% |
| Beta (5Y) | 0.01 | 0.49 |
| Employees | 81 | 49 |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 2 | 2 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 19.1× | 3.7× (better) |
| P/B | 4.5× | 1.2× (better) |
| Fair value | $0.950 | $7.43 |
| Margin of safety | −87.4% | 63.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −29.0% (better) | −70.1% |
| Revenue growth, 5Y average | 15.7% (better) | −5.4% |
| Net income growth (TTM) | – | −103% |
| EPS growth (TTM) | – | −104% |
| EPS growth, 5Y average | – | −14.7% |
| Profitability | ||
| Gross margin | 99.1% (better) | 54.4% |
| Operating margin | −131% | −20.8% (better) |
| Net margin | −147% | −5.2% (better) |
| Return on equity | −40.2% | −1.5% (better) |
| Return on invested capital | −163% | −23.6% (better) |
| Financial health | ||
| Debt / equity | 0.29 (better) | 0.00 |
| Current ratio | 13.37 | 21.72 (better) |
| Altman Z-score | −4.87 | 11.85 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 22.0% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 22.0% (better) |
| Ownership | ||
| Held by institutions | 81.9% | 48.5% |
| Held by insiders | – | 1.9% |
| Insider net buying, 12 months | $2.8M | – |
| Short interest, % of float | – | 5.1% |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- SIGA stock overview
- SIGA income statement
- SIGA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.